Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.

MLA

Gerds, Aaron T., et al. “Momelotinib versus Danazol in Symptomatic Patients with Anaemia and Myelofibrosis Previously Treated with a JAK Inhibitor (MOMENTUM): An Updated Analysis of an International, Double-Blind, Randomised Phase 3 Study.” The Lancet. Haematology, vol. 10, no. 9, Sept. 2023, pp. e735–46. EBSCOhost, https://doi.org/10.1016/S2352-3026(23)00174-6.

APA

Gerds, A. T., Verstovsek, S., Vannucchi, A. M., Al-Ali, H. K., Lavie, D., Kuykendall, A. T., Grosicki, S., Iurlo, A., Goh, Y. T., Lazaroiu, M. C., Egyed, M., Fox, M. L., McLornan, D., Perkins, A., Yoon, S.-S., Gupta, V., Kiladjian, J.-J., Granacher, N., Lee, S.-E., … Mesa, R. (2023). Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. The Lancet. Haematology, 10(9), e735–e746. https://doi.org/10.1016/S2352-3026(23)00174-6

Chicago

Gerds, Aaron T, Srdan Verstovsek, Alessandro M Vannucchi, Haifa Kathrin Al-Ali, David Lavie, Andrew T Kuykendall, Sebastian Grosicki, et al. 2023. “Momelotinib versus Danazol in Symptomatic Patients with Anaemia and Myelofibrosis Previously Treated with a JAK Inhibitor (MOMENTUM): An Updated Analysis of an International, Double-Blind, Randomised Phase 3 Study.” The Lancet. Haematology 10 (9): e735–46. doi:10.1016/S2352-3026(23)00174-6.